Can rivaroxaban be a drug of choice for treating heparin-induced thrombocytopenia in a patient with pulmonary thromboembolism?

Heparin-induced thrombocytopenia (HIT) is an adverse effect of heparin therapy (1). There are two types of HIT: non-immunomediated (HIT-I) and immunomediated (HIT-II) disorders. HIT-II is characterized by the formation of IgG antibodies against the heparin-PLT factor 4 complex (PF4) (1, 2). Bounded with heparin, this factor creates a neoantigen and stimulates the production of antibodies (2). Activated PLTs, along with the heparin/PF4 antibody complex attached to their surface, undergo aggregation and premature removal from the circulation, leading to thrombocytopenia and additionally to a procoagulant state with high potential for thrombus formation and thromboembolic events (3). T